Skip to content

uniQure QURE Price / book

Price / book at other companies

Ultragenyx Pharmaceutical logo
Ultragenyx PharmaceuticalRARE
316.5×+303×
Denali Therapeutics Inc. logo
Denali Therapeutics Inc.DNLI
3.3×+1.5×
CRISPR Therapeutics logo
CRISPR TherapeuticsCRSP
2.5×+0.9×
Krystal Biotech, Inc. logo
Krystal Biotech, Inc.KRYS
5.9×+0.6×
ALN
Alnylam PharmaceuticalsALNY
40.8×-41.2×
Beam Therapeutics logo
Beam TherapeuticsBEAM
2.1×+0.4×

Other financials

Income statement

See full
Revenue$3.6M+127%
Gross profit$3.3M+144%
Operating income-$45.7M-16.2%
Net income-$53.5M-22.7%
EPS (diluted)-$0.85-3.7%

Balance sheet

See full
Cash & equivalents$140.0M-35.6%
Total debt$63.3M-4.3%
Total equity$149.3M+343%
Total assets$778.7M+28.6%

Cash flow

See full
Operating cash flow-$38.2M+13.3%
CapEx$140.0K+11.1%
Free cash flow-$38.4M+13.2%

Valuation

See full
Market cap$3.09B+78.4%
Enterprise value$3.02B+124%
P/S170.9×+85.1×

Profitability

See full
Gross margin90.6%-2.9pp
Operating margin-1,059.7%+380pp
Net margin-1,154.4%+89.3pp
FCF margin-953.7%+169pp

Returns & leverage

See full
Return on equity-228.2%-11.6pp
Debt / equity0.4×-1.5×
Current ratio10.4×-1.6×

Where this comes from

Calculated from uniQure’s reported figures.

Based on the most recent quarter.

The official record: uniQure’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about uniQure's price / book.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is uniQure's price / book?
uniQure (QURE) reported price / book of 6.8× in Q1 2026.
How has uniQure's price / book changed year-over-year?
uniQure's price / book decreased by 59.8% year-over-year, from 17× to 6.8×.
What is the long-term trend for uniQure's price / book?
Over 4 years (2020 to 2025), uniQure's price / book has grown at a 2.3% compound annual growth rate (CAGR), from 6.8× to 7.5×.
What does price / book mean?
Market capitalization at the quarter end divided by shareholders' equity. The premium (or discount) the market assigns to the company's book equity.